Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Guillermo Izquierdo"'
Autor:
Francisco Carlos Pérez‐Miralles, Daniel Prefasi, Antonio García‐Merino, José Ramón Ara, Guillermo Izquierdo, Virginia Meca‐Lallana, Francisco Gascón‐Giménez, María Luisa Martínez‐Ginés, Lluis Ramió‐Torrentà, Lucienne Costa‐Frossard, Óscar Fernández, Sara Moreno‐García, Jorge Maurino, Joan Carreres‐Polo, Bonaventura Casanova
Publikováno v:
Brain and Behavior, Vol 11, Iss 4, Pp n/a-n/a (2021)
Abstract Background and purpose Evidence on regional changes resulting from neurodegenerative processes underlying primary progressive multiple sclerosis (PPMS) is still limited. We assessed brain region volumes and their relationship with disability
Externí odkaz:
https://doaj.org/article/1c68c742d928479ab6b1cd9c261aafe7
Autor:
José I. Fernández-Velasco, Enric Monreal, Jens Kuhle, Virginia Meca-Lallana, José Meca-Lallana, Guillermo Izquierdo, Celia Oreja-Guevara, Francisco Gascón-Giménez, Susana Sainz de la Maza, Paulette E. Walo-Delgado, Paloma Lapuente-Suanzes, Aleksandra Maceski, Eulalia Rodríguez-Martín, Ernesto Roldán, Noelia Villarrubia, Albert Saiz, Yolanda Blanco, Carolina Diaz-Pérez, Gabriel Valero-López, Judit Diaz-Diaz, Yolanda Aladro, Luis Brieva, Cristina Íñiguez, Inés González-Suárez, Luis A Rodríguez de Antonio, José M. García-Domínguez, Julia Sabin, Sara Llufriu, Jaime Masjuan, Lucienne Costa-Frossard, Luisa M. Villar
Publikováno v:
Frontiers in Immunology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
ObjectiveTo ascertain the role of inflammation in the response to ocrelizumab in primary-progressive multiple sclerosis (PPMS).MethodsMulticenter prospective study including 69 patients with PPMS who initiated ocrelizumab treatment, classified accord
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aede30012e664d82801b01e156d5c467
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16790
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16790
Autor:
Guillermo Izquierdo, Jorge Maurino, Lluís Ramió-Torrentà, Bonaventura Casanova, Daniel Prefasi, Jose R. Ara, Francisco Pérez-Miralles, Lucienne Costa-Frossard, Oscar Fernandez, Virginia Meca-Lallana, Antonio García-Merino, María L Martínez-Ginés, Sara Moreno-García, Francisco Gascón-Giménez, Joan Carreres-Polo
Publikováno v:
Brain and Behavior, Vol 11, Iss 4, Pp n/a-n/a (2021)
Brain and Behavior
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Scientia
Brain and Behavior, 2021, vol.11, núm. 4, p. e02044
Articles publicats (D-CM)
DUGiDocs – Universitat de Girona
Brain and Behavior
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Scientia
Brain and Behavior, 2021, vol.11, núm. 4, p. e02044
Articles publicats (D-CM)
DUGiDocs – Universitat de Girona
Background and purpose Evidence on regional changes resulting from neurodegenerative processes underlying primary progressive multiple sclerosis (PPMS) is still limited. We assessed brain region volumes and their relationship with disability progress
Autor:
Jeannette Lechner-Scott, Patrizia Sola, Pierre Grammond, Daniele Spitaleri, Jose Luis Sanchez-Menoyo, Raed Alroughani, Maria Trojano, Franco Granella, Tomas Kalincik, Cavit Boz, Diana Ferraro, Pamela A. McCombe, Bart Van Wijmeersch, Serkan Ozakbas, Alessandra Lugaresi, Raymond Hupperts, Guillermo Izquierdo, Francois Grand'Maison, Maria Pia Sormani, Vilija Jokubaitis, Steve Vucic, Eugenio Pucci, Marco Onofrj, Helmut Butzkueven, Amy Kunchok
Background: The magnetic resonance imaging in multiple sclerosis (MAGNIMS) score combines relapses and magnetic resonance imaging (MRI) lesions to predict disability outcomes in relapsing–remitting multiple sclerosis (RRMS) treated with interferon-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45c88175568290711a4210ee2ffffe11
http://hdl.handle.net/11567/1019781
http://hdl.handle.net/11567/1019781
Autor:
Francisco Barrero, Javier Mallada-Frechin, María Luisa Martínez-Ginés, María Eugenia Marzo, Virginia Meca-Lallana, Guillermo Izquierdo, José Ramón Ara, Celia Oreja-Guevara, José Meca-Lallana, Lucía Forero, Irene Sánchez-Vera, María José Moreno, in representation of the MS NEXT study investigators
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0230846 (2020)
PLoS One
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
PLoS ONE
Zaguán: Repositorio Digital de la Universidad de Zaragoza
Universidad de Zaragoza
PLoS One
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
PLoS ONE
Zaguán: Repositorio Digital de la Universidad de Zaragoza
Universidad de Zaragoza
Purpose The objective of this study was to characterize the demographic and clinical profile of RRMS patients receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clinical practice. Methods This observational, retrospective
Autor:
Jose Luis García De Veas Silva, Carmen Bermudo Guitarte, Guillermo Izquierdo Ayuso, Maria Isabel García-Sánchez, Paloma Menéndez-Valladares, Myriam Adorna Martínez
Publikováno v:
Autoimmunity reviews. 18(1)
The importance of studying the cerebrospinal fluid (CSF) in Multiple Sclerosis (MS) is included in the last McDonald criteria (2018). The study of oligoclonal IgG bands (OCGB) assay is strongly recommended in some situations in which MS diagnosis is
Autor:
Francois Grand'Maison, Raed Alroughani, Jeannette Lechner-Scott, Vincent Van Pesch, Michael Barnett, Maria Trojano, Franco Granella, Raymond Hupperts, Cavit Boz, Jose Luis Sanchez-Menoyo, Daniele Spitaleri, Eugenio Pucci, Patrizia Sola, Pierre Grammond, Pierre Duquette, Tomas Kalincik, Helmut Butzkueven, Marc Girard, Steve Vucic, Tim Spelman, Guillermo Izquierdo, Alessandra Lugaresi, Myintzu Min
Publikováno v:
Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 24, no.12, p. 1569-1577 (2018)
Background: The current best practice suggests yearly magnetic resonance imaging (MRI) to monitor treatment response in multiple sclerosis (MS) patients. Objective: To evaluate the current practice of clinicians changing MS treatment based on subclin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26f080394b049d52ec6eaa024df86be3
https://hdl.handle.net/2078.1/204684
https://hdl.handle.net/2078.1/204684
Autor:
Oscar Fernández, Guillermo Izquierdo, Victoria Fernández, Laura Leyva, Virginia Reyes, Miguel Guerrero, Antonio León, Carlos Arnaiz, Guillermo Navarro, Maria Dolores Páramo, Antonio De la Cuesta, Bernat Soria, Abdelkrim Hmadcha, David Pozo, Rafael Fernandez-Montesinos, Maria Leal, Itziar Ochotorena, Patricia Gálvez, Maria Angeles Geniz, Francisco Javier Barón, Rosario Mata, Cristina Medina, Carlos Caparrós-Escudero, Ana Cardesa, Natividad Cuende, Research Group Study EudraCT 2008-004015-35
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0195891 (2018)
idUS. Depósito de Investigación de la Universidad de Sevilla
instname
Digital.CSIC. Repositorio Institucional del CSIC
PLoS ONE
idUS. Depósito de Investigación de la Universidad de Sevilla
instname
Digital.CSIC. Repositorio Institucional del CSIC
PLoS ONE
[Background] Currently available treatments for secondary progressive multiple sclerosis(SPMS) have limited efficacy and/or safety concerns. Adipose-mesenchymal derived stem cells(AdMSCs) represent a promising option and can be readily obtained using
Autor:
Eva Havrdova, Dana Horakova, Pierre Grammond, Roberto Bergamaschi, Murat Terzi, Jeanette Lechner-Scott, Eugenio Pucci, Pierre Duquette, C. Ramo-Tello, Cavit Boz, Tim Spelman, Diana Ferraro, Guillermo Izquierdo, Patrizia Sola, Tomas Kalincik, Daniele Spitaleri, Marc Girard, Francois Grand'Maison, Vilija Jokubaitis, Vincent Van Pesch, Maria Trojano, Franco Granella, Alexandre Prat, Helmut Butzkueven, Alessandra Lugaresi, Celia Oreja-Guevara, G. Iuliano, Johannes Lorscheider
Publikováno v:
Petersen, T & MSBase Study Group 2017, ' Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS ', Neurology, vol. 89, no. 10, pp. 1050-1059 . https://doi.org/10.1212/WNL.0000000000004330
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Neurology, 89(10), 1050-1059. LIPPINCOTT WILLIAMS & WILKINS
Neurology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Neurology, 89(10), 1050-1059. LIPPINCOTT WILLIAMS & WILKINS
Neurology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Kermode, Allan/0000-0002-4476-4016; Ferraro, Diana/0000-0003-4818-3806; Lugaresi, Alessandra/0000-0003-2902-5589; Jokubaitis, Vilija G./0000-0002-3942-4340; McCombe, Pamela/0000-0003-2704-8517; Ramo-Tello, Cristina M/0000-0001-8643-5053; Oreja-Guevar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::904c0542296881aee21101758dd5a13a
http://hdl.handle.net/11585/606089
http://hdl.handle.net/11585/606089
Publikováno v:
PLoS ONE, Vol 12, Iss 4, p e0176174 (2017)
PLoS ONE
PLoS ONE
Fingolimod approval was based mainly on two clinical trials, FREEDOMS and TRANSFORMS, which demonstrated the efficacy and safety of fingolimod in patients with multiple sclerosis (MS). We present an observational study that validates these trials fin